My Watchlist

Top Indices

NASDAQ Composite

Standard & Poors 500

My Portfolio

Lucid Diagnostics Inc. - Common Stock (NQ:LUCD)

0.4110 +0.0833 (+25.42%)

Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Lucid Diagnostics Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Earnings Scheduled For November 13, 2023 ↗

November 13, 2023

Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.

Via Benzinga

Earnings Preview For Lucid Diagnostics ↗

November 10, 2023

Via Benzinga

Earnings Scheduled For August 14, 2023 ↗

August 14, 2023

Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.

Via Benzinga

Where Lucid Diagnostics Stands With Analysts ↗

May 17, 2023

Via Benzinga

Preview: Lucid Diagnostics's Earnings ↗

May 12, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

March 24, 2023

Via Benzinga

Lucid Diagnostics Earnings Perspective: Return On Capital Employed ↗

March 15, 2023

Via Benzinga

A Preview Of Lucid Diagnostics's Earnings ↗

March 13, 2023

Via Benzinga

Why PAVmed Shares Are Falling Today ↗

January 18, 2023

PAVmed Inc. (NASDAQ: PAVM) shares are trading lower after the company announced a workforce reduction of roughly 20% alongside other cost-cutting measures.

Via Benzinga

PAVmed, Lucid Diagnostics Pause Some Development Programs, Announce Layoffs ↗

January 18, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

January 17, 2023

Via Benzinga

PAVmed and Lucid Diagnostics Provide Strategic Business Update

January 17, 2023

From PAVmed Inc.

Via Business Wire

PAVmed and Lucid Diagnostics to Provide Strategic Business Update

January 11, 2023

From PAVmed Inc.

Via Business Wire

PAVmed Partners with Novosound on Ultrasound Imaging Technology

December 22, 2022

From PAVmed Inc.

Via Business Wire

Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry

December 08, 2022

From Lucid Diagnostics Inc.

Via Business Wire

PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform

December 15, 2022

From PAVmed Inc.

Via Business Wire

Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research

December 01, 2022

From Lucid Diagnostics Inc.

Via Business Wire

PAVmed Provides Business Update and Third Quarter 2022 Financial Results

November 15, 2022

From PAVmed Inc.

Via Business Wire

Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results

November 14, 2022

From Lucid Diagnostics Inc.

Via Business Wire

Lucid Diagnostics to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum

November 10, 2022

From Lucid Diagnostics Inc.

Via Business Wire

Lucid Diagnostics Commences Production of EsoCheck Devices with High-Volume Manufacturer

November 09, 2022

From Lucid Diagnostics Inc.

Via Business Wire

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2022

November 02, 2022

From Lucid Diagnostics Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 24, 2022

Via Benzinga

Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results

August 15, 2022

From Lucid Diagnostics Inc.

Via Business Wire

Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio

August 11, 2022

From Lucid Diagnostics Inc.

Via Business Wire

Newly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Screening Using Lucid Diagnostics’ EsoGuard® and EsoCheck® Technologies

August 04, 2022

From Lucid Diagnostics Inc.

Via Business Wire

Lucid Diagnostics’ Laboratory Executes Four New Participating Provider Agreements

August 02, 2022

From Lucid Diagnostics Inc.

Via Business Wire

Lucid Diagnostics to Hold a Business Update Conference Call on August 15, 2022

August 01, 2022

From Lucid Diagnostics Inc.

Via Business Wire

Lucid Diagnostics to Participate in the Canaccord 42nd Annual Growth Conference and the 7th Annual Needham Med Tech & Diagnostics 1x1 Conference

July 18, 2022

From Lucid Diagnostics Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 05, 2022

Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock rose 14.5% to $0.53 during Tuesday's after-market session. The company's market cap stands at $14.0 million.

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.